Jazz Reports Continued Adoption of Xywav for Narcolepsy and IH
Jazz Pharmaceutics says the benefits of reducing sodium intake resonate with prescribers as the large majority of new-to-oxybate narcolepsy patients continue to be prescribed Xywav.
Jazz Pharmaceutics says the benefits of reducing sodium intake resonate with prescribers as the large majority of new-to-oxybate narcolepsy patients continue to be prescribed Xywav.
The acquisition of Sunosi adds a high-potential commercial asset to Axsome’s late-stage neuroscience portfolio.
A common concern in narcolepsy and idiopathic hypersomnia is a feeling of having little control over symptoms, which can lead to despair. But disorders of excessive sleepiness do have both medication and non-medication treatment approaches.
The funding will allow for larger scale clinical studies, expanding partnerships in the EU and US, and expedited product development.
Read MoreThe FDA also published its summary of clinical superiority findings for Xywav for the treatment of cataplexy or excessive daytime sleepiness associated with narcolepsy.
Read MoreThirteen abstracts sponsored by Jazz Pharmaceuticals and five abstracts from investigator-sponsored trials will be presented at SLEEP 2021.
Read MoreThe AAN presentation further quantifies the previously reported Phase 3 top-line results.
Read MoreIt’s been an unusual year. But, mostly as usual, the US Food & Drug Administration continued to review device and drug applications across all fields of medicine.
Read MoreA literature review from Stanford University looks at how the popular narcolepsy medication sodium oxybate impacts heart health.
Read MoreResults of the double-blind, placebo-controlled, randomized-withdrawal, multicenter study were previously presented at World Sleep 2019.
Read More“There is significant need for greater awareness of idiopathic hypersomnia, which can severely impact a person’s daily life, and can often be misdiagnosed or undiagnosed over a substantial period of time.”
Read MoreWith financial support from Jazz Pharmaceuticals, the American Heart Association will create sleep-related educational multimedia content.
Read MoreThe FDA approved a new oxybate formulation for excessive daytime sleepiness or cataplexy in narcolepsy. Should your patients switch?
Read MoreHighlights include presentations on Xywav, a lower sodium oxybate iindicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.
Read MoreMarketed by Jazz Pharmaceuticals, Xywav is for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
Read MoreSleep professionals and the general public have misperceptions about the neurological sleep disorder. How many did you believe?
Read MoreSleep Review annually rounds up the sleep medicine devices, pharmaceuticals, and more that earned US Food and Drug Administration clearance.
Read MoreThe FDA accepted for filing with Priority Review the Jazz Pharmaceuticals plc’s NDA seeking marketing approval for JZP-258, an investigational medicine for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
Read More